Inovio Pharmaceuticals (INO)
(Real Time Quote from BATS)
$11.43 USD
-0.57 (-4.75%)
Updated May 20, 2024 11:34 AM ET
3-Hold of 5 3
F Value F Growth F Momentum F VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
INO 11.43 -0.57(-4.75%)
Will INO be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for INO based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for INO
Equillium, Inc. (EQ) Reports Q1 Loss, Tops Revenue Estimates
Does Inovio (INO) Have the Potential to Rally 122.92% as Wall Street Analysts Expect?
INO: What are Zacks experts saying now?
Zacks Private Portfolio Services
CymaBay Therapeutics Inc. (CBAY) Reports Q4 Loss, Misses Revenue Estimates
Wall Street Analysts Predict a 146.39% Upside in Inovio (INO): Here's What You Should Know
Inovio (INO) Moves 17.4% Higher: Will This Strength Last?
Other News for INO
Inovio Pharmaceuticals Inc. stock underperforms Friday when compared to competitors
Inovio Pharmaceuticals Inc. stock outperforms competitors on strong trading day
Inovio Pharmaceuticals, Inc. (INO) Presents at 2024 RBC Capital Markets Global Healthcare Conference (Transcript)
Analysts Are Bullish on Top Healthcare Stocks: Merck & Company (MRK), Inovio Pharmaceuticals (INO)
RBC Capital Reaffirms Their Hold Rating on Inovio Pharmaceuticals (INO)